Differences in cancer survival by type of insurance

December 4, 2017

(HealthDay)—From 1997 to 2014, improvements in cancer survival were mainly limited to patients with private or Medicare insurance, according to a study published online Nov. 30 in JAMA Oncology.

Libby Ellis, Ph.D., from the Cancer Prevention Institute of California in Fremont, and colleagues examined trends in by health insurance status from January 1997 to December 2014. Data were included for 1,149,891 patients diagnosed with breast, prostate, colorectal, or , or melanoma.

The researchers found that survival improvements were almost entirely limited to patients with private or Medicare insurance; survival was largely unchanged or declined for patients with other public or no insurance. Cancer-specific mortality was higher in uninsured patients relative to privately insured patients, for all cancers except prostate; the largest disparities were seen from 2009 to 2014 for breast (hazard ratio [HR], 1.72), lung (HR, 1.18 for men and 1.32 for women), and colorectal cancer (HR, 1.30 for women). For all cancers except lung, mortality was higher for patients with other public insurance; the largest disparities were seen from 2009 to 2014 for breast (HR, 1.25), prostate (HR, 1.17), and colorectal cancer (HR, 1.16 for men and 1.11 for women).

"Survival disparities for men with prostate cancer and women with lung or increased significantly over time, reflecting a lack of improvement in survival for patients with other public or no insurance," the authors write.

Explore further: Insurance linked to black-white survival disparities in colorectal cancer

More information: Abstract/Full Text
Editorial (subscription or payment may be required)

Related Stories

Insurance linked to black-white survival disparities in colorectal cancer

November 14, 2017
Health insurance coverage differences account for nearly one-half of the black-white survival disparity in colorectal cancer patients, according to a new study. The study, published in Gastroenterology, reinforces the importance ...

Heart failure is as 'malignant' as some common cancers

May 4, 2017
A new analysis finds that, despite advances in care, men and women with a diagnosis of heart failure continue to have worse survival rates than patients with certain common cancers.

Insurance plays significant role in breast cancer disparities

October 16, 2017
Differences in insurance account for a substantial proportion of the excess risk of death from breast cancer faced by black women, according to a new study. The study, appearing in Journal of Clinical Oncology, concludes ...

Does health insurance status affect childhood cancer survival?

September 11, 2017
A new study examines whether insurance status may affect survival in children diagnosed with cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings suggest largely similar ...

More cancers diagnosed at early stage following increase in health insurance coverage

May 18, 2017
An analysis of nearly 273,000 patients showed that between 2013 and 2014 there was a 1 percent increase in the percentage of breast, lung, and colorectal cancers diagnosed at the earliest, most treatable stage. Considering ...

Number of newly diagnosed cancer patients without insurance drops in first year of ACA

October 19, 2017
The number of newly diagnosed cancer patients who were uninsured fell by one-third in the first year of the Affordable Care Act's implementation, according to research from Indiana University.

Recommended for you

Study tracks evolutionary transition to destructive cancer

February 23, 2018
Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Researchers use a molecular Trojan horse to deliver chemotherapeutic drug to cancer cells

February 23, 2018
A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

An under-the-radar immune cell shows potential in fight against cancer

February 23, 2018
One of the rarest of immune cells, unknown to scientists a decade ago, might prove to be a potent weapon in stopping cancer from spreading in the body, according to new research from the University of British Columbia.

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.